Alkermes plc.: insider trades · United States · SEC (Form 4)

About Alkermes plc.

Alkermes plc. (ticker: ALKS) is a biopharmaceutical company listed on the Nasdaq Global Select Market in the United States, with a strategic focus on neuroscience. Its global headquarters is in Dublin, Ireland, while the company maintains a significant operational and commercial footprint in the United States, where most of its marketing and execution capabilities are concentrated. Founded in 1987, Alkermes evolved from a specialty drug-delivery and formulation technology business into an integrated biopharma company combining development, manufacturing, and commercialization. For investors, it is best understood as a mid-cap specialty pharma name with a commercial base and a meaningful pipeline, exposed to psychiatric, addiction, and neurological disorders. ([alkermes.com](https://www.alkermes.com/about-us?utm_source=openai)) The commercial portfolio is centered on VIVITROL, ARISTADA/ARISTADA INITIO, and LYBALVI, which target long-standing unmet needs in alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. Alkermes also highlights its manufacturing capabilities and royalty/manufacturing revenues, giving the group a hybrid profile that combines branded pharmaceuticals with product development and platform expertise. In recent company disclosures, Alkermes has emphasized that its portfolio and pipeline are focused on central nervous system disorders, with a strategy built around expanding existing brands and advancing new clinical assets. ([investor.alkermes.com](https://investor.alkermes.com/news-releases/news-release-details/alkermes-plc-reports-third-quarter-2025-financial-results/?utm_source=openai)) From a competitive standpoint, Alkermes is a focused specialist rather than a broadly diversified large-cap pharma company. Its edge comes from a combination of established brands, medication-delivery know-how, and a commercial infrastructure geared toward therapeutic areas where adherence is often a major challenge. In antipsychotics and addiction medicine, the company competes in crowded markets, but its differentiated formulations and established market presence support a distinct positioning. The company also operates internationally, with activities in the United States, Ireland, and other regions, although its revenue base remains heavily tied to the U.S. market. ([stockanalysis.com](https://stockanalysis.com/stocks/alks/company/?utm_source=openai)) Recent developments are noteworthy. In 2026, Alkermes reported first-quarter results and said it expects to initiate a Phase 3 program for alixorexton in narcolepsy. That matters strategically because it shows the company is trying to broaden its pipeline beyond marketed products and pursue a new opportunity in sleep and neurology. The company continues to report quarterly performance updates and market disclosures that point to ongoing activity across its core franchises. In short, ALKS is a neuroscience-focused health care name listed on Nasdaq in the United States, with upside tied to both commercial execution and future clinical readouts. ([investor.alkermes.com](https://investor.alkermes.com/static-files/fff86401-d90f-4ef5-97ff-16775edb0cbe?utm_source=openai))